Dean Investment Associates’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.76M Buy
45,552
+1,785
+4% +$104K 0.39% 128
2025
Q4
$2.36M Sell
43,767
-5,971
-12% -$287K 0.34% 133
2025
Q3
$2.24M Sell
49,738
-1,980
-4% -$92.5K 0.31% 138
2025
Q2
$2.39M Buy
51,718
+1,045
+2% +$51.3K 0.35% 139
2025
Q1
$3.09M Sell
50,673
-3,620
-7% -$211K 0.46% 97
2024
Q4
$3.07M Sell
54,293
-24,503
-31% -$1.37M 0.44% 99
2024
Q3
$4.08M Sell
78,796
-5,499
-7% -$258K 0.55% 63
2024
Q2
$3.5M Sell
84,295
-3,116
-4% -$139K 0.5% 79
2024
Q1
$4.74M Buy
87,411
+16,648
+24% +$848K 0.65% 52
2023
Q4
$3.63M Sell
70,763
-14,987
-17% -$787K 0.52% 84
2023
Q3
$4.98M Buy
85,750
+850
+1% +$52.1K 0.82% 30
2023
Q2
$5.43M Buy
84,900
+17,777
+26% +$1.19M 0.88% 30
2023
Q1
$4.65M Buy
67,123
+5,314
+9% +$375K 0.74% 45
2022
Q4
$4.45M Buy
61,809
+7,002
+13% +$528K 0.76% 42
2022
Q3
$3.9M Buy
54,807
+727
+1% +$52.7K 0.79% 37
2022
Q2
$4.16M Sell
54,080
-22,493
-29% -$1.71M 0.81% 29
2022
Q1
$5.59M Buy
76,573
+1,092
+1% +$73.3K 1% 13
2021
Q4
$4.71M Sell
75,481
-2,516
-3% -$148K 0.83% 30
2021
Q3
$4.62M Sell
77,997
-610
-0.8% -$40.2K 0.87% 23
2021
Q2
$5.25M Sell
78,607
-121
-0.2% -$7.89K 0.97% 13
2021
Q1
$4.97M Sell
78,728
-745
-0.9% -$46.4K 0.94% 13
2020
Q4
$4.93M Sell
79,473
-3,456
-4% -$213K 1.02% 7
2020
Q3
$5M Sell
82,929
-1,536
-2% -$92.4K 1.2% 6
2020
Q2
$4.97M Sell
84,465
-469
-0.6% -$28.1K 1.19% 6
2020
Q1
$4.73M Sell
84,934
-557
-0.7% -$34K 1.01% 10
2019
Q4
$5.49M Sell
85,491
-28,680
-25% -$1.64M 0.86% 24
2019
Q3
$5.79M Buy
114,171
+1,026
+0.9% +$48.2K 0.85% 27
2019
Q2
$5.13M Buy
113,145
+71,342
+171% +$3.32M 0.74% 47
2019
Q1
$1.99M Buy
+41,803
New +$2.08M 0.29% 131

Other funds holding BMY

Dean Investment Associates's BMY Position: Q1 2026 in Review

Dean Investment Associates increased its Bristol-Myers Squibb (BMY) stake by 4.1% in Q1 2026, buying an estimated $104K and bringing the position to 45,552 shares worth $2.76M. The position accounts for 0.39% of the portfolio, ranked #128.

Dean Investment Associates first reported a position in BMY in Q1 2019 and has held it in 29 quarters since. The position peaked at $5.79M in Q3 2019. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Dean Investment Associates held 45,552 shares of Bristol-Myers Squibb worth $2.76M as of Q1 2026.
  • Dean Investment Associates bought 1,785 Bristol-Myers Squibb shares in Q1 2026, an estimated $104K.
  • Bristol-Myers Squibb made up 0.39% of Dean Investment Associates's portfolio in Q1 2026, its #128 holding.
  • Dean Investment Associates first reported a position in Bristol-Myers Squibb in Q1 2019 and has held it in 29 quarters since.
  • Dean Investment Associates's Bristol-Myers Squibb position peaked at $5.79M in Q3 2019.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Dean Investment Associates's 13F filing for Q1 2026, filed 15 May 2026.